ClinicalTrials.gg

TargetBeta

PRMT5

protein arginine methyltransferase 5 · also SKB1Hs, HRMT1L5, SKB1 · 7BS protein arginine methyltranferases

10 programs in company-led studies act on PRMT5, from 10 companies: 1 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
navlimetostatBristol-Myers Squibbphase 31010 running–a judged reading
JBI-778ruleJubilant Therapeutics Indiaphase 222 running–the studies' text
PRMT5 Inhibitor AZD3470AstraZenecaphase 222 running–a judged reading
PRMT5 Inhibitor BAY 3713372ruleBayerphase 211 running–NCIt
PRMT5 Inhibitor TNG456ruleTango Therapeuticsphase 211 running–NCIt
PRMT5 Inhibitor BGB-58067ruleBeOne Medicinesphase 122 running–NCIt
onametostatruleJohnson & Johnsonphase 121 running–NCIt
PRMT5 Inhibitor SH3765ruleNanjing Sanhome Pharmaceuticalphase 121 running–NCIt
PEP08rulePharmaEnginephase 111 running–the studies' text
PRMT5 Inhibitor IDE892ruleIDEAYA Biosciencesphase 111 running–NCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.